[go: up one dir, main page]

NO20004788L - Kombinasjon for behandling av alkohol- og medikamentavhengighet inneholdende en opoidantagonist og en NMDA- reseptorkompleksmodulator - Google Patents

Kombinasjon for behandling av alkohol- og medikamentavhengighet inneholdende en opoidantagonist og en NMDA- reseptorkompleksmodulator

Info

Publication number
NO20004788L
NO20004788L NO20004788A NO20004788A NO20004788L NO 20004788 L NO20004788 L NO 20004788L NO 20004788 A NO20004788 A NO 20004788A NO 20004788 A NO20004788 A NO 20004788A NO 20004788 L NO20004788 L NO 20004788L
Authority
NO
Norway
Prior art keywords
nmda receptor
receptor complex
alcohol
treatment
combination
Prior art date
Application number
NO20004788A
Other languages
English (en)
Other versions
NO319313B1 (no
NO20004788D0 (no
Inventor
Martine Daoust
Yves Bonhomme
Philippe Durbin
Original Assignee
Lipha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipha filed Critical Lipha
Publication of NO20004788D0 publication Critical patent/NO20004788D0/no
Publication of NO20004788L publication Critical patent/NO20004788L/no
Publication of NO319313B1 publication Critical patent/NO319313B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20004788A 1998-03-26 2000-09-25 Anvendelse av en synergistisk kombinasjon av en opioidantagonist og en NMDA reseptorkompleksmodulator for behandling av alkoholavhengighet NO319313B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98400723A EP0945133A1 (en) 1998-03-26 1998-03-26 Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator
PCT/EP1999/002337 WO1999048500A1 (en) 1998-03-26 1999-03-26 Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a nmda receptor complex modulator

Publications (3)

Publication Number Publication Date
NO20004788D0 NO20004788D0 (no) 2000-09-25
NO20004788L true NO20004788L (no) 2000-11-24
NO319313B1 NO319313B1 (no) 2005-07-11

Family

ID=8235311

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004788A NO319313B1 (no) 1998-03-26 2000-09-25 Anvendelse av en synergistisk kombinasjon av en opioidantagonist og en NMDA reseptorkompleksmodulator for behandling av alkoholavhengighet

Country Status (17)

Country Link
US (1) US6512009B1 (no)
EP (2) EP0945133A1 (no)
KR (1) KR20010034678A (no)
AT (1) ATE230993T1 (no)
AU (1) AU758569B2 (no)
BR (1) BR9909138A (no)
CA (1) CA2325739C (no)
CZ (1) CZ296367B6 (no)
DE (1) DE69904922T2 (no)
DK (1) DK1063995T3 (no)
ES (1) ES2190205T3 (no)
HU (1) HU226555B1 (no)
NO (1) NO319313B1 (no)
PL (1) PL193241B1 (no)
RU (1) RU2226107C2 (no)
SK (1) SK284623B6 (no)
WO (1) WO1999048500A1 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2336879C (en) * 1998-07-20 2010-06-01 Peptech Limited Sustained-release formulations comprising peptides, polypeptides, proteins or nucleic acids as active ingredients
US8052982B2 (en) 1998-07-20 2011-11-08 Peptech Animal Health Pty Limited Bioimplant formulation comprising lecithin and stearin
WO2001052851A1 (en) * 2000-01-22 2001-07-26 Albert Shulman Methods for the treatment of substance abuse
EP1262196A3 (en) * 2001-05-23 2002-12-18 Pfizer Products Inc. Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence
DE10129265A1 (de) * 2001-06-18 2003-01-02 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
ES2187288B1 (es) * 2001-09-24 2004-09-16 Garbil Pharma Investigacion Chile Ltda Aminas como agentes anti-alcoholismo.
US7736665B2 (en) 2002-05-31 2010-06-15 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine
EP2959893A1 (en) 2002-12-13 2015-12-30 DURECT Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
US20040224020A1 (en) * 2002-12-18 2004-11-11 Schoenhard Grant L. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
SI1610791T1 (sl) * 2003-03-31 2011-05-31 Titan Pharmaceuticals Inc Implantibilna polimerna naprava za zadržano sproščanje dopaminskega agonista
US20050031668A1 (en) * 2003-05-30 2005-02-10 Patel Rajesh A. Implantable polymeric device for sustained release of nalmefene
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
CA2673481A1 (en) * 2006-12-19 2008-06-26 University Of Virginia Patent Foundation Combined effects of topiramate and ondansetron on alcohol consumption
WO2009088414A2 (en) 2007-12-06 2009-07-16 Durect Corporation Oral pharmaceutical dosage forms
NZ588037A (en) 2008-02-28 2012-08-31 Univ Virginia Patent Found Serotonin transporter gene SLC6A4 and treatment of alcoholism
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
CA2804174A1 (en) 2010-07-02 2012-01-05 University Of Virginia Patent Foundation Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
CA2848211A1 (en) 2011-09-09 2013-03-14 University Of Virginia Patent Foundation Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
RU2476209C1 (ru) * 2012-02-29 2013-02-27 Станислав Анатольевич Кедик Имплантируемое лекарственное средство на основе налтрексона для лечения пациентов, зависимых от алкоголя или опиатов
CA2905131A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
GB201308440D0 (en) * 2013-05-10 2013-06-19 Dalgleish Angus Therapeutic
KR102413459B1 (ko) 2016-07-06 2022-06-24 듀렉트 코퍼레이션 약물 조성물, 장벽 층 및 약물 층을 갖는 경구 투여 형태
US20240350433A1 (en) * 2021-08-17 2024-10-24 Yale University Treatment compositions and methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882335A (en) * 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
EP0828489A4 (en) * 1996-03-13 2001-04-04 Univ Yale Smoking cessation treatments using naltrexone and related compounds

Also Published As

Publication number Publication date
BR9909138A (pt) 2000-12-05
HUP0101546A3 (en) 2002-10-28
AU758569B2 (en) 2003-03-27
HU226555B1 (en) 2009-03-30
HK1032542A1 (en) 2001-07-27
CA2325739A1 (en) 1999-09-30
DK1063995T3 (da) 2003-03-10
HUP0101546A2 (hu) 2001-09-28
DE69904922T2 (de) 2004-01-08
ATE230993T1 (de) 2003-02-15
KR20010034678A (ko) 2001-04-25
EP1063995B1 (en) 2003-01-15
CA2325739C (en) 2007-05-15
EP1063995A1 (en) 2001-01-03
CZ296367B6 (cs) 2006-02-15
DE69904922D1 (de) 2003-02-20
CZ20003525A3 (cs) 2001-04-11
AU3522699A (en) 1999-10-18
WO1999048500A1 (en) 1999-09-30
NO319313B1 (no) 2005-07-11
SK14282000A3 (sk) 2001-05-10
PL343069A1 (en) 2001-07-30
EP0945133A1 (en) 1999-09-29
NO20004788D0 (no) 2000-09-25
ES2190205T3 (es) 2003-07-16
RU2226107C2 (ru) 2004-03-27
US6512009B1 (en) 2003-01-28
SK284623B6 (sk) 2005-08-04
PL193241B1 (pl) 2007-01-31

Similar Documents

Publication Publication Date Title
NO20004788D0 (no) Kombinasjon for behandling av alkohol- og medikamentavhengighet inneholdende en opoid-antagonist og en NMDA reseptorkompleksmodulator
ES2181055T3 (es) Formulaciones galenicas que contienen antagonistas de opiaceos.
DK0812195T3 (da) Farmaceutisk sammensætning til piperidinoalkanolforbindelser
EE9700241A (et) Farmatseutiline kompositsioon transdermaalseks manustamiseks
HUP9701694A3 (en) Indolinone derivatives for the treatment of disease, use thereof, pharmaceutical compositions containing these compounds
DK0747050T4 (da) Farmaceutiske sammensætninger, der indeholder irbesartan
PL326203A1 (en) (methylsulphonyl)phenyl-2-(5)-furanones as cox-2 inhibitors
NO973479L (no) Substituerte heterosykliske forbindelser, fremgangsmåte for fremstilling og farmasöytiske blandinger inneholdende samme
IL116673A (en) Stable oral pharmaceutical composition containing an acid labile benzimidazole
ATE339406T1 (de) Chinazoline verbindungen als heilmittel
DZ2614A1 (fr) Compositions pharmaceutiques topiques contenant des dérivés de résorcinol.
DE69634053D1 (de) Oral anzuwendende Arzneizusammensetzung enthaltend 2-Methyl-thienobenzodiazepin
SE9904505D0 (sv) Novel compounds
ID29994A (id) Komposisi farmasi untuk melawan ccr5 terdiri dari turunan anilida
HUP9801711A3 (en) Use of substituted imidazolidin-2,4-dion compounds for producing pharmaceutical compositions with analgetic effect
ES2171723T3 (es) 3,4-diaril-2-hidroxi-2,5-dihidrofuranos como profarmacos de inhibidores de cox-2.
TR199801861T2 (xx) Farmas�tik olarak yararl� bile�imler.
AU1549500A (en) Use of n-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis
TR200000737T2 (tr) İkame edilmiş kroman türevleri.
NO20021898L (no) Farmasoytisk sammensetning inneholdende ciclesonid for applikasjon til mukosa
BR0013313A (pt) Derivados substituìdos de pirrolidino-2,3,4- triona-3-oxina eficazes como antagonistas de receptores de nmda
IL145645A0 (en) N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists
MX9708394A (es) Composicion farmaceutica que contiene clorhidrato de tiagabina y el proceso para su preparacion.
DE60134735D1 (de) Neue neurokinin-antagonisten zum gebrauch als arzneimittel
DK0758312T3 (da) Substituerede fusionerede og broforbundne bicykliske forbindelser som terapeutiske midler

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees